Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer after Primary Radiotherapy Failure: Results from a Prospective Clinical Trial

No prospective published data exist on focal salvage high-dose-rate (HDR) brachytherapy for recurrent prostate cancer. In the present prospective trial, we evaluated toxicity, quality of life and efficacy of such an approach in patients with multiparametric MRI-visible, biopsy-confirmed local recurrence after previous definitive external beam radiotherapy. We found that it had a favorable toxicity profile, was associated with promising biochemical control and yielded MRI response in the majority of patients.

https://ift.tt/2Kstu9R